Formosa Pharmaceuticals, Inc.

6838

TW0006838006

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
55.1 ^TWD	0.00%		+1.10%	+10.31%

09/05	Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery	CI
07/03	Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops	CI

Formosa Pharmaceuticals, Inc.(TPEX:6838) added to S&P Global BMI Index

September 18, 2023 at 09:30 am IST

Latest news about Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery	09/05	CI
Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops	07/03	CI
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery	05/03	CI
US FDA approves Eyenovia's eye drug, Formosa Pharma says	05/03	RE
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02	CI
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	26/01	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/12	CI
Formosa Pharmaceuticals, Inc.(TPEX:6838) added to S&P Global BMI Index	18/23/18	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	11/23/11	CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery	05/23/05	CI
Grand Pharmaceutical Group's Eye Drops Show Safety in Phase 2, 3 Trials	12/23/12	MT
Formosa Pharmaceuticals, Inc. Announces Phase III Clinical Study of a Global Innovative Hormone Nanosuspension Eye Drops Successfully Reached Clinical Endpoint	11/23/11	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics	15/23/15	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	11/22/11	CI
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery	09/22/09	CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery	12/22/12	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI
HCmed Innovations, Formosa Laboratories, and Formosa Pharmaceuticals Signs MoU to Form A Global CDMO for Inhalation Treatment Drugs	07/22/07	CI
China Grand Pharmaceutical and Healthcare Holdings Limited Announces That the Group Recently Reached an Exclusive Product Licensing Agreement with Formosa Pharmaceuticals, Inc	03/21/03	CI
Formosa Pharmaceuticals, Inc. completed the acquisition of Activus Pharma Co., Ltd. from Sosei Group Corporation.	10/17/10	CI
Formosa Pharmaceuticals, Inc. agreed to acquire Activus Pharma Co., Ltd. from Sosei Group Corporation for approximately TWD 370 million.	04/17/04	CI

Chart Formosa Pharmaceuticals, Inc.

Duration

Period

More charts

Formosa Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the development of early drug candiate and pre-clinical drug products. The Company also conducts the research and development of nanotechnology platform and dosage form design, and uses the patented nano platform to overcome the challenges of low dissociation rate and poor bioavailability in the development of pharmaceutical dosage forms. In the research and development projects, the ophthalmic drug APP13007 has entered the phase III clinical trial stage, and its indications are anti-ocular postoperative inflammation, and its main appeal is to reduce postoperative inflammation and pain. TSY-0110 has entered the preclinical stage to develop antibody-drug conjugate (ADC) to cure breast cancer. The innovative small molecule compound MPT0E028 has completed the first phase of clinical trials and is expected to be used in the field of anti-cancer therapy.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FORMOSA PHARMACEUTICALS, INC.	+10.31%	227M
ELI LILLY AND COMPANY	+61.92%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.88%	359B
MERCK & CO., INC.	+15.34%	325B
ABBVIE INC.	+9.06%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.91%	177B
PFIZER, INC.	+2.24%	165B